Importantly, inhibition of FGF (by PD161570), ERK (by U0126), or WNT (by PNU74654) signaling resensitizes the FLT3-mutant AML cells to AC220 treatment, providing a new option of targeting alternative signaling pathways in parallel to enhance the therapeutic response in AML. This evidence concerns the gene FLT3 and acute myeloid leukemia.